Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Dec 21, 2020

(R) Changes to Cantargia’s nomination committee

Dec 16, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 564 million

Dec 15, 2020

(R) Cantargia announces intention of a directed share issue

Nov 26, 2020

BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

Nov 12, 2020

(R) Cantargia publishes interim report for third quarter 2020

Oct 20, 2020

(R) Nomination Committee appointed ahead of 2021 Annual General Meeting

Oct 13, 2020

(R) Extraordinary general meeting in Cantargia AB (publ)

Oct 8, 2020

(R) Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy

Oct 2, 2020

(R) Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab

Sep 23, 2020

(R) Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye